NASDAQ · IKT
Healthcare · Biotechnology
$2.31
Down-$0.10 (-4.15%)
Updated Sep 1, 2026, 8:40 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
IKT closed at $2.31 after 21 trading sessions, up 4.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $2.41 | $2.44 | $2.30 | $2.31 | 329.87K |
| Aug 28, 2026 | $2.48 | $2.48 | $2.371 | $2.41 | 307.96K |
| Aug 27, 2026 | $2.48 | $2.50 | $2.40 | $2.47 | 202.09K |
| Aug 26, 2026 | $2.50 | $2.51 | $2.4301 | $2.49 | 244.7K |
| Aug 25, 2026 | $2.53 | $2.54 | $2.46 | $2.50 | 453.44K |
| Aug 24, 2026 | $2.41 | $2.54 | $2.345 | $2.50 | 735.93K |
| Aug 21, 2026 | $2.38 | $2.415 | $2.37 | $2.39 | 309.32K |
| Aug 20, 2026 | $2.45 | $2.47 | $2.33 | $2.35 | 539.99K |
| Aug 19, 2026 | $2.44 | $2.515 | $2.43 | $2.45 | 644.99K |
| Aug 18, 2026 | $2.36 | $2.41 | $2.31 | $2.40 | 343.97K |
| Aug 17, 2026 | $2.41 | $2.42 | $2.32 | $2.39 | 489.78K |
| Aug 14, 2026 | $2.39 | $2.435 | $2.37 | $2.41 | 227.89K |
| Aug 13, 2026 | $2.43 | $2.46 | $2.33 | $2.41 | 360.73K |
| Aug 12, 2026 | $2.38 | $2.47 | $2.38 | $2.40 | 296.95K |
| Aug 11, 2026 | $2.48 | $2.515 | $2.41 | $2.45 | 580.84K |
| Aug 10, 2026 | $2.44 | $2.525 | $2.42 | $2.46 | 479.22K |
| Aug 7, 2026 | $2.38 | $2.475 | $2.38 | $2.47 | 386.85K |
| Aug 6, 2026 | $2.39 | $2.49 | $2.385 | $2.41 | 422.92K |
| Aug 5, 2026 | $2.46 | $2.50 | $2.33 | $2.40 | 1.11M |
| Aug 4, 2026 | $2.25 | $2.465 | $2.24 | $2.44 | 1.26M |
| Aug 3, 2026 | $2.19 | $2.285 | $2.155 | $2.21 | 486.56K |
The latest Smart Investors Daily articles mentioning IKT.
IKT research
Company profile and research snapshot.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 10, 2026 | Oppenheimer | Outperform | — |
| Mar 4, 2026 | Ladenburg Thalmann | Buy | — |
| Jan 21, 2026 | B of A Securities | Buy | — |
| Dec 11, 2025 | Cantor Fitzgerald | Overweight | — |
| Mar 28, 2025 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · Mar 4, 2026
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $4.
ChartMill · Feb 24, 2026
Unusual volume stocks are being observed in Tuesday's session.
Yahoo · Feb 22, 2026
The stock market has been treading water so far this year, with the S&P 500 up roughly 1% while the Nasdaq has slipped 1.5%. Tech stocks have struggled to regain last year’s momentum as investors reassess the durability of AI-driven spending, the margin impact of massive capital expenditures, and whether growth rates can justify the premium multiples many companies still command. That skepticism toward richly valued mega-cap tech has pushed investors to look elsewhere for returns, and biotech ha
Yahoo · Feb 18, 2026
ServiceTitan offers cloud software for field service management, generating recurring revenue from a broad base of service professionals.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IKT.
